GlassScriptPhysician profile
Heather M Green
NPI 1427355940
$3,447.52
in general payments reported to CMS, 2019-2025
33 companies · $730 in 2025
The $730 reported for 2025 was more than what 83% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $455 · 2022: $703 · 2023: $842 · 2024: $718 · 2025: $730.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,268 · Education: $22.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,268.02 |
| Education | $22.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $584.28 | 2021-2024 | Farxiga, Evusheld, Lokelma |
| Calliditas Therapeutics US INC. | $366.61 | 2023-2025 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $341.03 | 2022-2025 | Jynarque |
| Amgen INC. | $327.97 | 2021-2025 | Tavneos, Parsabiv |
| Fresenius USA Marketing, INC. | $297.23 | 2021-2025 | Velphoro, Velphoro |
| Bayer Healthcare Pharmaceuticals INC. | $190.55 | 2021-2025 | |
| Glaxosmithkline, LLC. | $175.75 | 2021-2024 | Benlysta, Jesduvroq |
| Daiichi Sankyo INC. | $130.43 | 2021-2024 | Injectafer |
| Mallinckrodt Hospital Products INC. | $101.56 | 2021-2025 | Terlivaz, Acthar |
| Vifor Pharma, INC. | $91.93 | 2021-2023 | Veltassa |
| Aurinia Pharma U.S., INC. | $91.74 | 2022-2025 | Lupkynis |
| Akebia Therapeutics INC | $90.16 | 2021-2024 | Auryxia, Vafseo |
| Travere Therapeutics, INC. | $71.28 | 2024-2025 | |
| Horizon Therapeutics Plc | $59.01 | 2023 | Krystexxa |
| Ardelyx, INC. | $53.36 | 2024-2025 | Ibsrela |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $46.84 | 2024-2025 | Ozempic, Rybelsus |
| Opko Pharmaceuticals, LLC | $37.66 | 2022-2023 | Rayaldee |
| Alexion Pharmaceuticals, INC. | $35.61 | 2022-2024 | Ultomiris |
| Lilly USA, LLC | $34.91 | 2024 | Jardiance |
| Genzyme Corporation | $34.67 | 2022-2023 | |
| Recordati_rare_diseases_inc. | $34.05 | 2021-2022 | |
| Recor Medical INC | $31.42 | 2025 | Paradise Ultrasound Renal Denervation System |
| Organogenesis INC. | $31.26 | 2021-2022 | |
| Veloxis Pharmaceuticals, INC. | $25.15 | 2025 | Envarsus |
| Abbott Laboratories | $21.82 | 2023 | Jeti |
| Lemaitre Vascular, INC. | $21.27 | 2023 | Anastoclip Gc 8cm (Medium) |
| Renalytix Ai, INC. | $20.65 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Eusa Pharma (US) LLC | $18.29 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.88 | 2024 | Jardiance |
| Vbi Vaccine (Delaware) INC. | $17.86 | 2022 | |
| Pharmacosmos Therapeutics INC. | $15.93 | 2022 | |
| Scpharmaceuticals INC. | $14.68 | 2025 | |
| Mannkind Corporation | $14.68 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.